JP2015503540A5 - - Google Patents

Download PDF

Info

Publication number
JP2015503540A5
JP2015503540A5 JP2014549478A JP2014549478A JP2015503540A5 JP 2015503540 A5 JP2015503540 A5 JP 2015503540A5 JP 2014549478 A JP2014549478 A JP 2014549478A JP 2014549478 A JP2014549478 A JP 2014549478A JP 2015503540 A5 JP2015503540 A5 JP 2015503540A5
Authority
JP
Japan
Prior art keywords
alkyl
group
cycloalkyl
heterocyclyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014549478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503540A (ja
JP6130398B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/077025 external-priority patent/WO2013098373A1/en
Publication of JP2015503540A publication Critical patent/JP2015503540A/ja
Publication of JP2015503540A5 publication Critical patent/JP2015503540A5/ja
Application granted granted Critical
Publication of JP6130398B2 publication Critical patent/JP6130398B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014549478A 2011-12-29 2012-12-28 新規アゼチジン誘導体、その医薬組成物及び使用 Expired - Fee Related JP6130398B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11196046 2011-12-29
EP11196046.4 2011-12-29
PCT/EP2012/077025 WO2013098373A1 (en) 2011-12-29 2012-12-28 New azetidine derivatives, pharmaceutical compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2015503540A JP2015503540A (ja) 2015-02-02
JP2015503540A5 true JP2015503540A5 (enExample) 2016-02-18
JP6130398B2 JP6130398B2 (ja) 2017-05-17

Family

ID=47557123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014549478A Expired - Fee Related JP6130398B2 (ja) 2011-12-29 2012-12-28 新規アゼチジン誘導体、その医薬組成物及び使用

Country Status (4)

Country Link
US (1) US8530461B2 (enExample)
EP (1) EP2797885B1 (enExample)
JP (1) JP6130398B2 (enExample)
WO (1) WO2013098373A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014061693A1 (ja) * 2012-10-17 2014-04-24 塩野義製薬株式会社 新規非芳香族炭素環又は非芳香族複素環誘導体
MX2016002479A (es) * 2013-09-12 2016-05-31 Pfizer Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
EP3059225A4 (en) 2013-10-17 2017-09-06 Shionogi & Co., Ltd. Novel alkylene derivative
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
EP3225618B1 (en) * 2014-11-26 2020-05-06 Takeda Pharmaceutical Company Limited Bicyclic compound
EP3247701B1 (en) * 2015-01-20 2021-09-22 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds, compositions and method of using thereof
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
US10287269B2 (en) 2015-03-26 2019-05-14 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
EP3291817B1 (en) 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
DK3402480T3 (da) 2016-01-11 2021-06-28 Epicentrx Inc Sammensætninger og fremgangsmåder til intravenøs administration af 2-brom-1-(3,3-dinitroazetidin-1-yl)ethanon
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス,インコーポレーテッド 化合物及びその使用
ES3025460T3 (en) 2017-01-06 2025-06-09 Janssen Pharmaceutica Nv Scd inhibitor for the treatment of neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
EP3768269B1 (en) 2018-03-23 2025-08-20 Janssen Pharmaceutica NV Compounds and uses thereof
WO2020154571A1 (en) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN113480541B (zh) * 2019-03-07 2022-09-02 湖南化工研究院有限公司 咪唑并吡啶化合物及其中间体的制备方法
CA3134510A1 (en) * 2019-03-22 2020-10-01 Yumanity Therapeutics, Inc. Compounds and uses thereof
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
US20250134858A1 (en) * 2022-02-10 2025-05-01 Epicentrx, Inc. Compositions and methods for treatment of nafld and nash and related dyslipidemias

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
WO2005116009A1 (en) * 2004-05-18 2005-12-08 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
CA2619450C (en) 2005-09-01 2013-10-22 Eli Lilly And Company 6-n-linked heterocycle-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
DE102005055726A1 (de) 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
MX2008008337A (es) * 2005-12-21 2008-09-03 Schering Corp Fenoxipiperidinas y sus analogos utiles como antagonistas de histamina h3.
WO2007095602A2 (en) * 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
JPWO2007119833A1 (ja) * 2006-04-14 2009-08-27 武田薬品工業株式会社 含窒素複素環化合物
CA2654792A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR064965A1 (es) * 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
WO2010043052A1 (en) 2008-10-17 2010-04-22 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2010127212A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
TW201206911A (en) 2010-04-27 2012-02-16 Takeda Pharmaceutical Bicyclic compound

Similar Documents

Publication Publication Date Title
JP2015503540A5 (enExample)
JP2010530431A5 (enExample)
EP1857457A3 (en) Benzimidazole derivative and its use as AII receptor antagonist
RU2014105624A (ru) Соединения индазола, способ их применения и фармацевтическая композиция
JP2016516043A5 (enExample)
JP2008503533A5 (enExample)
JP2011504903A5 (enExample)
JP2014526501A5 (enExample)
JP2014530900A5 (enExample)
JP2008501760A5 (enExample)
RU2017114355A (ru) Производные нафтиридина в качестве антагонистов альфа v бета 6 интегрина для лечения, в частности, фиброзных заболеваний
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
RU2013149174A (ru) Новое имидазооксазиновое соединение или его соль
JP2014504622A5 (enExample)
JP2010515715A5 (enExample)
JP2012512907A5 (enExample)
JP2006524222A5 (enExample)
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
JP2013508279A5 (enExample)
JP2007530493A5 (enExample)
JP2018502101A5 (enExample)
JP2017531678A5 (enExample)
JP2007532607A5 (enExample)
JP2014528464A5 (enExample)
JP2016531868A5 (enExample)